{"id":63028,"date":"2022-04-29T12:18:15","date_gmt":"2022-04-29T10:18:15","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=63028"},"modified":"2023-10-05T08:10:27","modified_gmt":"2023-10-05T08:10:27","slug":"alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","title":{"rendered":"Alzheimer y aducanumab. Hablamos de sus controversias en una nueva tertulia de actualidad con la Dra. Merc\u00e8 Boada y el dr. Albert Le\u00f3n"},"content":{"rendered":"

El pasado 20 de abril<\/strong> tuvo lugar en Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> la tertulia de actualidad \u201cAlzheimer y aducanumab. Controversias\u201d<\/strong>, a cargo de la Dra. Merc\u00e8 Boada<\/strong>, neur\u00f3loga, cofundadora y directora m\u00e9dica de la Fundaci\u00f3n ACE<\/a><\/strong> y el Dr. Albert Le\u00f3n<\/strong>, director de la Unidad de Memoria del Servicio de Neurolog\u00eda del Hospital de Sant Pau y coordinador del programa Alzheimer de CIBERNED. Aina Surroca<\/strong>, secretaria de la Junta de Gobierno del COFB<\/strong> y responsable de la Comisi\u00f3n Delegada de Formaci\u00f3n Continua<\/strong>, fue la encargada de moderar la sesi\u00f3n<\/strong>. <\/p>\n\n\n\n

\"D'esquerra
De izquierda a derecha: La Dra. Merc\u00e8 Boada, el dr. Albert Le\u00f3n y la secretaria de la Junta de Gobierno del COFB, Aina Surroca. <\/figcaption><\/figure>\n\n\n\n

Alzheimer, aducanumab y otros f\u00e1rmacos<\/strong><\/h2>\n\n\n\n

Una nueva era por tratamiento del Alzheimer<\/strong> <\/span><\/strong><\/h3>\n\n\n\n

Seg\u00fan expuso el dr. Le\u00f3n, \u201cestamos en un momento muy excitante de la historia <\/strong>de la enfermedad de Alzheimer<\/strong> porque realmente ha habido muchos cambios<\/strong>. Hay que poner en contexto d\u00f3nde estamos con eladucanumab<\/strong> y con la resto de tratamientos<\/strong>\u201c. Y a\u00f1adi\u00f3: \u201cNos encontramos en una era en la que sobre todo hay f\u00e1rmacos biol\u00f3gicos<\/strong> fundamentalmente porque en las estrategias previas de inhibici\u00f3n de v\u00edas productoras de amiloide y otras dianas no han mostrado resultados positivos\u201d. <\/p>\n\n\n\n

Asimismo, el dr. Le\u00f3n apunt\u00f3 que \u201cen Europa, el 17 de diciembre, elAgencia Europea del Medicamento<\/strong> (EMA, por sus siglas en ingl\u00e9s) se pronunci\u00f3 y dijo que no aprobar\u00eda, que no autorizar\u00eda el uso en Europa del f\u00e1rmaco aducanumab<\/strong>“. <\/p>\n\n\n\n

\"El
El dr. Albert Le\u00f3n, durante la tertulia de actualidad. <\/figcaption><\/figure>\n\n\n\n

En este sentido, seg\u00fan expuso el doctor \u201cla compa\u00f1\u00eda est\u00e1 preparando una apelaci\u00f3n<\/strong> y no hay una resoluci\u00f3n definitiva<\/strong>. Pero la resoluci\u00f3n inicial fue negativa y la compa\u00f1\u00eda, a ra\u00edz de esta situaci\u00f3n, decide iniciar -por recomendaci\u00f3n de la FDA y de expertos independientes- un nuevo estudio confirmatorio<\/strong> con aducanumab<\/strong>, en fase 3b\/4<\/strong>, con m\u00e1s de 1.500 pacientes<\/strong> con Alzheimer de entre 60 y 85 a\u00f1os<\/strong>, ya que parece que los pacientes mayores tienen mayor respuesta que los pacientes m\u00e1s j\u00f3venes\u201d. <\/p>\n\n\n\n

Aparte deladucanumab<\/strong>, el doctor detall\u00f3 que \u201chay otros f\u00e1rmacos<\/strong> que est\u00e1n en la fase final, la fase 3. De hecho, hay algunos que ya han tenido resultados positivos en estudios previos como lecanemab<\/strong>, donanemab<\/strong> o gantenerumab<\/strong>. Algunos de ellos terminar\u00e1n la fase 3 cumplida a finales de a\u00f1o. O sea, entre finales de este ya principios del pr\u00f3ximo a\u00f1o tendremos noticias y ser\u00e1 muy importante. Y todos ellos tienen datos de que hay una cierta se\u00f1al cl\u00ednica <\/strong>en las fases previas\u201d. <\/p>\n\n\n\n

Por \u00faltimo, el Dr. Le\u00f3n<\/strong> concluy\u00f3 que \u201cel tratamiento del Alzheimer ha entrado en una nueva era<\/strong> y que, pese a la controversia<\/strong>, se ha aprobado el primer biol\u00f3gico para el Alzheimer<\/strong>. Hay otros biol\u00f3gicos<\/strong> que est\u00e1n en elhorizonte <\/strong>y que es cuesti\u00f3n de tiempo que esto llegue a Europa. Creo que ahora disponemos de un tiempo de oro realmente para preparar el terreno<\/strong> para que estemos preparados tanto los hospitales como los diferentes centros, tanto en el diagn\u00f3stico como a la hora de adecuar las infraestructuras para prepararnos por una nueva era<\/strong> en la enfermedad de Alzheimer<\/strong>“.<\/p>\n\n\n\n

La proximidad del farmac\u00e9utico y su conocimiento del enfermo.<\/span><\/strong><\/h3>\n\n\n\n

La Dra. Boada<\/strong> durante su intervenci\u00f3n<\/strong> afirm\u00f3 que la definici\u00f3n de enfermedad de Alzheimer<\/strong> ha cambiado: \u201cDejamos de hablar de demencia tipo Alzheimer<\/strong>, que es lo que hac\u00edamos, para hablar de enfermedad de Alzheimer<\/strong>. Esta \u00faltima <\/strong>est\u00e1 focalizada en buscar aquellos marcadores biol\u00f3gicos <\/strong>que indiquen que el cerebro tiene la marca de que la ciencia ha dicho que configuraba esta enfermedad. <\/p>\n\n\n\n

\"La
La Dra. Merc\u00e8 Boada, en un momento de su intervenci\u00f3n.<\/figcaption><\/figure>\n\n\n\n

Respecto a la controversia con el aducanumab<\/strong>, en una enfermedad tan larga como el alzheimer, la directora m\u00e9dica de la Fundaci\u00f3n ACE record\u00f3 que \u201cen 6 meses de tratamiento no podemos ver nada<\/strong>\u201c. Sin embargo, \u201ctenemos que dar pasos peque\u00f1os, y si bien, el beneficio cl\u00ednico que tenemos por ahora es escaso, nos va muy bien para entender la enfermedad desde un punto de vista biol\u00f3gico<\/strong>“.<\/p>\n\n\n\n

En cuanto al papel de los farmac\u00e9uticos<\/strong>, la Dra. Boada explic\u00f3 que estos profesionales sanitarios \u201cnos pueden ayudar, son los que m\u00e1s conocen al enfermo. La farmacia<\/strong> es extremadamente cercana<\/strong>“.<\/p>\n\n\n

\n\n\n

Seg\u00fan el EMA, elevidencia cient\u00edfica<\/strong> no demuestra lo suficiente queaducanumab<\/strong> sea efectivo para el tratamiento en adultos en fases iniciales de la enfermedad de Alzheimer<\/strong>. La agencia europea ha concluido que, pese a que el f\u00e1rmaco ha demostrado reducir la presencia de amiloide en el cerebro, la investigaci\u00f3n actual no relaciona este hecho con una mejora cl\u00ednica de los pacientes.<\/p>\n\n\n\n

La autorizaci\u00f3n de aducanumab en EE.UU. est\u00e1 sujeta a un nuevo estudio postcomercializaci\u00f3n <\/strong>para demostrar su eficacia cl\u00ednica. En Europa, se decidi\u00f3 que no queda demostrado que los posibles beneficios superen los posibles riesgos. Por el momento, la farmac\u00e9utica Biogen ha comunicado que pedir\u00e1 que reexaminen la solicitud en Europa.<\/p> <\/div>","protected":false},"excerpt":{"rendered":"

El pasado 20 de abril tuvo lugar en el Colegio de Farmac\u00e9uticos de Barcelona (COFB) la tertulia de actualidad \u201cAlzheimer y aducanumab. Controversias\u201d, a cargo de la Dra. Merc\u00e8 Boada, neur\u00f3loga, cofundadora y directora m\u00e9dica de la Fundaci\u00f3n ACE y el dr. Albert Le\u00f3n, director de la Unidad de Memoria del Servicio [\u2026]<\/p>","protected":false},"author":1,"featured_media":67922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[512,64,18,19,53,68,69,70,684,76,140,141],"class_list":["post-63028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-alzheimer","tag-atencio-farmaceutica","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics","tag-farmacia","tag-farmacia-comunitaria","tag-formacio","tag-memoria","tag-oficina-de-farmacia","tag-tertulia-dactualitat","tag-tertulies-dactualitat"],"yoast_head":"\nAlzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat "Alzheimer i aducanumab. Controv\u00e8rsies", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat "Alzheimer i aducanumab. Controv\u00e8rsies", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T10:18:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-05T08:10:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3\",\"datePublished\":\"2022-04-29T10:18:15+00:00\",\"dateModified\":\"2023-10-05T08:10:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"},\"wordCount\":907,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"keywords\":[\"alzheimer\",\"Atenci\u00f3 farmac\u00e8utica\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics\",\"Farm\u00e0cia\",\"farm\u00e0cia comunit\u00e0ria\",\"Formaci\u00f3\",\"Mem\u00f2ria\",\"Oficina de farm\u00e0cia\",\"tert\u00falia d'actualitat\",\"tert\u00falies d'actualitat\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\",\"name\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"datePublished\":\"2022-04-29T10:18:15+00:00\",\"dateModified\":\"2023-10-05T08:10:27+00:00\",\"description\":\"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \\\"Alzheimer i aducanumab. Controv\u00e8rsies\\\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","og_locale":"es_ES","og_type":"article","og_title":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","og_url":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2022-04-29T10:18:15+00:00","article_modified_time":"2023-10-05T08:10:27+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","type":"image\/jpeg"}],"author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3","datePublished":"2022-04-29T10:18:15+00:00","dateModified":"2023-10-05T08:10:27+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"},"wordCount":907,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","keywords":["alzheimer","Atenci\u00f3 farmac\u00e8utica","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics","Farm\u00e0cia","farm\u00e0cia comunit\u00e0ria","Formaci\u00f3","Mem\u00f2ria","Oficina de farm\u00e0cia","tert\u00falia d'actualitat","tert\u00falies d'actualitat"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","url":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/","name":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d'actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3 - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","datePublished":"2022-04-29T10:18:15+00:00","dateModified":"2023-10-05T08:10:27+00:00","description":"El passat 20 d'abril va tenir lloc al COFB la tert\u00falia d'actualitat \"Alzheimer i aducanumab. Controv\u00e8rsies\", a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei de Neurologia de l'Hospital de Sant Pau.","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2022\/04\/29\/alzheimer-i-aducanumab-en-vam-parlar-de-les-seves-controversies-a-una-nova-tertulia-dactualitat-amb-la-dra-merce-boada-i-el-dr-albert-lleo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Alzheimer i aducanumab. En vam parlar de les seves controv\u00e8rsies a una nova tert\u00falia d’actualitat amb la Dra. Merc\u00e8 Boada i el Dr. Albert Lle\u00f3"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",1024,576,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Alzheimer_21042022_2-1024x576-1.jpg",18,10,false]},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 20 d’abril va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la tert\u00falia d’actualitat “Alzheimer i aducanumab. Controv\u00e8rsies”, a c\u00e0rrec de la Dra. Merc\u00e8 Boada, neur\u00f2loga, cofundadora i directora m\u00e8dica de la Fundaci\u00f3 ACE i el Dr. Albert Lle\u00f3, director de la Unitat de Mem\u00f2ria del Servei […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/63028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=63028"}],"version-history":[{"count":2,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/63028\/revisions"}],"predecessor-version":[{"id":68737,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/63028\/revisions\/68737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media\/67922"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=63028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=63028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=63028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}